<DOC>
	<DOCNO>NCT01697007</DOCNO>
	<brief_summary>Electroporation increase efficiency DNA priming term immune response lead dose spar DNA vaccine regimen . Furthermore increased DNA vaccine concentration reduce number shot necessary deliver full dose induce comparable immune response low DNA vaccine concentration .</brief_summary>
	<brief_title>A Phase II Trial Assess Safety Immunogenicity DNA Priming Administered ID Zetajet® With Without ID Derma Vax™ Electroporation Followed IM MVA Boosting Healthy Volunteers Tanzania Mozambique</brief_title>
	<detailed_description />
	<criteria>Willing undergo counsel HIV test . Have negative antigen/antibody ELISA HIV infection . Able give inform consent . Basic ability read write . Satisfactory completion assessment understand prior enrolment define 90 % correct answer three opportunity take test . Resident region study take place . At low risk HIV infection . Verbal assurance adequate birth control measure . Healthy evidence clinical laboratory measure At risk HIV infection . Active tuberculosis . A history immunodeficiency , ongoing medical and/or psychiatric condition and/or chronic illness require continuous frequent medical intervention . Autoimmune disease . Hives severe eczema . Substance abuse problem . History grandmal epilepsy . Received blood blood product immunoglobulins past 3 month . Receiving immunosuppressive therapy systemic corticosteroid cancer chemotherapy . Use experimental therapeutic agent within 30 day study entry . History cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>